KING PHARMACEUTICALS AND WYETH ANNOUNCE RESTRUCTURING OF CO-PROMOTION AGREEMENT FOR ALTACE

King Pharmaceuticals, Inc. and Wyeth Pharmaceuticals, a division of Wyeth, announced today that they have entered into an Amended and Restated Co-Promotion Agreement regarding King's product ALTACE (ramipril), an angiotensin converting enzyme (ACE) inhibitor. Effective January 1, 2007, King will assume full responsibility for the selling and marketing of ALTACE. For the remainder of 2006, the Wyeth sales force will continue to promote the product with King; and Wyeth will receive a fee thereafter through 2010.

Yahoo News (http://biz.yahoo.com/prnews/060706/nyth086.html?.v=52)